Cambridge Healthtech Institute’s 2nd Annual

Bispecific Antibodies for Cancer Immunotherapy

Engineering Next-Generation Biotherapeutics in Immuno-Oncology

August 6-7, 2019



Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the next generation of immunotherapy. Cambridge Healthtech Institute’s Second Annual Bispecific Antibodies for Cancer Immunotherapy conference will showcase preclinical, translational and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T-cell-redirecting bispecific biologics, overcoming T-cell exhaustion, as well as strategies to improve efficacy and reduce toxicity, and engineer the next generation of bi- and multi-specific biologics. 

T-CELL ENGAGING BISPECIFIC ANTIBODIES

Bispecific T-Cell Engaging Molecules: Mechanism of Action and Activity in Hematological Malignancies
Tara Arvedson, PhD, Director, Oncology Research, Amgen

Multiple Avenues to T-Cell Activation with Bispecific Antibodies
John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor

COBRAs – Development of a Potent, Conditionally Active Bispecific T-Cell Engager Platform
Bob DuBridge, PhD, EVP, Research & CTO, Maverick Therapeutics

BISPECIFIC ANTIBODIES FOR COMBINATION IMMUNOTHERAPY

Development of a Novel Bispecific Immune Modulating Antibody Targeting PD-L1 and CD27
Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics

Unbiased Functional Screening Unlocks Novel Biology for Targeted and IO Bispecific Antibodies
Mark Throsby, PhD, Executive Vice President & CSO, Merus NV

ENGINEERING MULTI-SPECIFIC ANTIBODIES

Unleash the Potential of Multispecific Antibodies to Fight Cancer
Jijie Gu, PhD, Director, Immunology Target Validation & Lead Discovery, Research Fellow, Biologics Research, AbbVie

A Novel, Monovalent Multi-Specific Antibody-Based Molecule that Simultaneously Modulates PD-L1 and 4-1BB Exhibits Potent Anti-Tumoral Activity In Vivo
Alexandre Simonin, PhD, Director, mAb Discovery, Numab Innovation AG

Targeting T Cell Agonists to the Tumor Environment with Multi-Specific Human Heavy Chain Antibodies
Wim van Schooten, PhD, CSO, TeneoBio


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com